肾小球转录组学预测假定良性IgA肾病的长期结局并识别治疗策略
研究对假定良性IgA肾病患者诊断时肾活检肾小球mRNA测序,比较15例进展者与21例非进展者,用双组分分类器筛选出8个进展基因和9个非进展基因,平均可在临床记录进展前21.6年预测疾病进展,准确率88%、敏感性75%、特异性100%。
要点
- 肾小球转录组可区分假定良性IgA肾病未来进展者与非进展者。
- 8个进展基因和9个非进展基因平均提前21.6年预测进展。
- 预测准确率88%、敏感性75%、特异性100%。
核心结论
- 假定良性IgA肾病患者诊断时肾小球mRNA测序可区分未来进展者与非进展者。
研究设计与样本
- 回顾性分析成人假定良性IgA肾病患者肾活检肾小球,21例稳定临床缓解为非进展者,15例在25年内临床进展为进展者。
主要发现
- 基于1 240个差异表达基因,用双组分分类器识别8个进展基因和9个非进展基因,包括APOL5和ZXDC。
- 这些基因平均在临床记录进展前21.6年预测疾病进展,准确率88%、敏感性75%、特异性100%。
- 转录组数据中10个基因与外部全基因组关联研究数据集重叠,但基因集富集检验无统计学显著性。
- 在DrugBank中识别45个药物靶点,包括血管紧张素原,为sparsentan的靶点。
关键数值与推荐
- 双组分分类器预测进展:准确率88%、敏感性75%、特异性100%,平均提前21.6年。
临床怎么用
- 对假定良性IgA肾病患者,诊断时肾小球转录组学可能辅助识别未来进展高风险者。
局限性
- 基因集富集检验无统计学显著性。
- 研究样本量有限,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Some patients diagnosed with benign IgA nephropathy (IgAN) develop a progressive clinical course, not predictable by known clinical or histopathological parameters. To assess if gene expression can differentiate between progressors and non-progressors with assumed benign IgAN, we tested microdissected glomeruli from archival kidney biopsy sections from adult patients with stable clinical remission (21 non-progressors) or from 15 patients that had undergone clinical progression within a 25-year time frame. Based on 1 240 differentially expressed genes from patients with suitable sequencing results, we identified eight IgAN progressor and nine non-progressor genes using a two-component classifier. These genes, including APOL5 and ZXDC, predicted disease progression with 88% accuracy, 75% sensitivity and 100% specificity on average 21.6 years before progressive disease was clinically documented. APOL lipoproteins are associated with inflammation, autophagy and kidney disease while ZXDC is a zinc-finger transcription factor modulating adaptive immunity. Ten genes from our transcriptomics data overlapped with an external genome wide association study dataset, although the gene set enrichment test was not statistically significant. We also identified 45 drug targets in the DrugBank database, including angiotensinogen, a target of sparsentan (dual antagonist of the endothelin type A receptor and the angiotensin II type 1 receptor) currently investigated for IgAN treatment. Two validation cohorts were used for substantiating key results, one by immunohistochemistry and the other by nCounter technology. Thus, glomerular mRNA sequencing from diagnostic kidney biopsies from patients with assumed benign IgAN can differentiate between future progressors and non-progressors at the time of diagnosis.
引用
- Rivedal M, Mikkelsen H, Marti HP, et al. Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy. Kidney Int. 2023. PMID: 38154557. doi:10.1016/j.kint.2023.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。